PBAC rejects Cushing’s syndrome treatment again
A second bid to include osilodrostat on the PBS failed to demonstrate cost-effectiveness, the PBAC says.
The PBAC has rejected a twice-daily medication for Cushing’s syndrome for the second time because of its cost, despite acknowledging it was an effective therapy and there was a high clinical need.
Osilodrostat (Isturisa) was approved by the TGA in 2022 to treat adults with endogenous Cushing’s syndrome, but the oral non-steroidal cortisol synthesis inhibitor is yet to be sold in Australia.
